Alfasigma S.p.A.

Alfasigma to participate at United European Gastroenterology Week -12-15 October

Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company headquartered in Italy, announced its participation in the United European Gastroenterology (UEG) Week 2024. Taking place from 12-15 October in Vienna, the international conference is one of the most important annual conferences in this therapeutic area.

During the conference, several Alfasigma driven presentations and abstracts focused on ulcerative colitis and chronic intestinal pseudo-obstruction will be showcased and Alfasigma will be based at booth 26 in Hall B.

This is the first conference in which Alfasigma is participating since becoming the marketing authorisation holder for Jyseleca® in the European Union and Great Britain, announced in August and September respectively. The market authorization transfers followed the transaction completed on January 31, 2024, in which Alfasigma acquired the Jyseleca® (filgotinib) business from Galapagos NV.


Alfasigma S.p.A.

Alfasigma announces the Completion of Marketing Authorisation Transfer for Jyseleca® in the European Union

Alfasigma S.p.A. today announced the completion of the transfer of marketing authorization of Jyseleca® (filgotinib) from Galapagos NV (Euronext & NASDAQ: GLPG) to the Italian pharmaceutical company in the European Union.

The marketing authorization transfer was approved by the European Commission following a positive opinion from the European Medicines Agency (EMA) on 2nd August 2024.

This update follows the transaction completed on 31st January 2024 in which Alfasigma acquired the Jyseleca® (filgotinib) business from Galapagos. With this acquisition, Alfasigma consolidated its commitment to specialty pharmaceuticals, adding an innovative product to its portfolio in the gastrointestinal and rheumatological therapeutic areas, that addresses very important patients’ unmet needs.

Jyseleca® (filgotinib) is a once-daily oral JAK1 preferential inhibitor, a class of drugs with an innovative mechanism of action and already approved for two indications: Rheumatoid Arthritis (approved in 2020) and Ulcerative Colitis (approved in 2021).

Furthermore, Alfasigma Group enhanced its presence in the European markets with the acquisition of Jyseleca®, and expanded in the Northern European markets: today Alfasigma Group has branches in Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Poland, Portugal, Romania, Spain, Sweden, Switzerland, and the UK.